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Abstract 
Objective 
There is little published data reporting outcomes for those found to have a chronic total 
coronary occlusion (CTO) which is electively treated medically versus those treated by PCI. 
We sought to compare long-term clinical outcomes between patients treated by PCI and 
elective medical therapy in a consecutive cohort of patients with an identified CTO. 
Methods 
Patients found to have a CTO on angiography between January 2002 and December 2007 in a 
single tertiary centre were identified using a dedicated database. Those undergoing CTO PCI 
and elective medical therapy to the CTO were propensity matched to adjust for baseline 
clinical and angiographic differences.  
Results 
In total 1957 patients were identified, a CTO was treated by PCI in 405(20.7%) and medical 
therapy in 667(34.1%), 885(45.2%) patients underwent CABG. Of those treated by PCI or 
medical therapy, propensity score matching identified 294 pairs of patients, PCI was 
successful in 177 patients (60.2%). All-cause mortality at 5 years was 11.6% for CTO PCI 
and 16.7% for medical therapy HR 0.63(0.40-1.00) p=.052. The composite of 5-year death or 
MI occurred in 13.9% of the CTO PCI group and 19.6% in the medical therapy group, HR 
0.64(0.42 to 0.99), p=.043. Amongst the CTO PCI group, if the CTO was revascularized by 
any means during the study period, 5 year mortality was 10.6%, compared with 18.3% in 
those not revascularized in the medical therapy group, HR 0.50(0.28-0.88, p=.016). 
Conclusions 
Revascularization, but not necessarily PCI of a CTO is associated with improved long-term 
survival relative to medical therapy alone.       
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Key messages 
What is already known? 
A number of studies have demonstrated an associated clinical outcome benefit if patients 
with a chronic total coronary occlusion (CTO) are treated by successful PCI versus failed 
PCI. However, there is little data comparing a strategy of PCI versus medical/conservative 
therapy of the CTO. 
What does this study add? 
Although we did not identify a statistically significant difference in 5-year all-cause mortality 
between groups, we demonstrate a significant associated reduction in the composite of death 
or myocardial infarction at 5 years if a CTO is treated by PCI rather than medical therapy, 
analysed by intention to treat. The difference appears to be driven by the increased rates of 
CTO territory revascularisation (including by CABG) during the study period in the CTO 
PCI group. 
How might this impact on clinical practice? 
This study adds weight to the suggestion that revascularisation of a CTO is associated with a 
prognostic benefit, although not necessarily by PCI. 
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Introduction 
A chronic total coronary occlusion(CTO) is present in between one fifth and half of 
patients who have significant coronary artery disease1,2. There is a large body of 
observational data suggesting an association between successful CTO percutaneous coronary 
intervention(PCI) and improved clinical outcomes, including survival3,4. These findings are 
contrary to the findings of randomized trials comparing medical therapy with  PCI of stable 
non-occlusive coronary disease, where except for reduced urgent revascularization in the 
FAME-2 trial5(which did include a very small proportion of CTOs), no overall outcome 
benefit has been demonstrated6–10.  
There is little published data reporting outcomes for those found to have a CTO which 
is electively treated medically versus those treated by PCI; a comparison which is more 
pertinent to clinical decision making than PCI success versus failure. Practice with respect to 
revascularization of CTOs varies between clinicians, so it is likely that pre-treatment 
characteristics overlap. In addition, important confounding variables such as overall 
angiographic complexity cannot be accounted for if registries from which data is collected do 
not include them4.  
The aim of this study is to compare long-term clinical outcomes in a consecutive 
cohort of patients with an identified CTO on angiography between these two treatment 
groups. Our primary outcome was difference in 5-year all-cause mortality between groups 
propensity matched for clinical and angiographic pre-treatment characteristics. 
Methods 
Definitions 
A CTO was defined as complete coronary occlusion of ≥3 months duration with TIMI 
grade 0 flow. Duration of occlusion was estimated as time from symptom onset, MI or from 
previous angiography (outside the study period) to angiography. CTO PCI success was 
defined as stenting of the target vessel with <30% residual stenosis and TIMI grade III flow 
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to the distal vessel. Patients were grouped according to treatment strategy 
(PCI/CABG/medical therapy) on an intention-to-treat basis. If a patient had multi-vessel 
disease and was treated by PCI but the CTO was treated medically, they were included in the 
medical therapy group.  
Study population 
All patients undergoing coronary angiography or PCI in a single tertiary centre were 
prospectively entered into a dedicated database including demographic and procedural 
details; each patient record was validated by a clinical audit officer. Patients with an occluded 
coronary artery on angiography between 1st January 2002 and 31st December 2007 were 
identified(n=4457). We excluded those treated for acute MI in the territory of the occluded 
vessel in the preceding 3 months, with prior CABG, mitral or aortic valve disease of 
moderate severity or greater, active neoplastic disease and those already included in the 
study. The final cohort included 1957 patients. Medical records and coronary angiograms 
were reviewed retrospectively to give additional angiographic, procedural and clinical details 
not routinely recorded in the database.  
Ethics 
The study complies with the Declaration of Helsinki. The study protocol was 
approved by the local research ethics committee (13/YH/0036). As the study was 
retrospective and we were unable to obtain informed consent from those patients with our 
primary outcome of mortality, we obtained approval from the National Confidentiality 
Advisory Group(CAG 3-06(PR3)/2013) to include clinical data and outcome measures 
without informed consent. 
Angiographic assessment 
Overall angiographic complexity was quantified by the use of the Syntax Score11,12. 
Complexity of the individual CTO was assessed by the J-CTO score13. Left ventricular 
function was assessed by left ventriculography, and where not available by 
echocardiography. 
6 
 
 
Outcome measures 
Our primary outcome was 5-year all cause mortality amongst propensity matched 
groups. Data on patient mortality and international classification of disease cause of death 
was obtained from Office of National Statistics death certification records.  
Secondary outcomes included hospitalization for myocardial infarction (MI), the 
composite of death and MI, and PCI or coronary artery bypass graft surgery (CABG) at 
follow-up. Follow-up data was obtained through linkage by The National Institute for 
Cardiac Outcomes Research, obtained from the Myocardial Infarction National Audit Project, 
British Cardiovascular Intervention Society Central Cardiac Audit Database and the National 
Adult Cardiac Surgery Audit respectively.  
Statistical analysis 
Data is presented as percentages and mean±SD or median(inter-quartile range) as 
appropriate. Differences in proportions are tested with a chi-squared test or Fisher’s exact 
test, and differences in continuous variables with a Student t-test or Mann-Whitney U-test.  
Propensity matching was performed to minimize any selection bias due to the differences in 
clinical characteristics between PCI and elective medical therapy treatment groups. For each 
patient in the cohort a propensity score indicating the likelihood of a CTO being treated by 
PCI was calculated by the use of a non-parsimonious multivariable logistic regression model. 
Co-variates included in the logistic regression model to calculate the propensity score were: 
age, gender, previous PCI, previous MI, diabetes mellitus, smoking status, peripheral 
vascular disease(PVD), hypertension, chronic kidney disease(CKD)stage >3, chronic lung 
disease, cerebrovascular disease, Canadian Cardiovascular Society(CCS)class, New York 
Heart Association(NYHA)class, presentation (stable angina, unstable angina(UA)/non-ST 
elevation myocardial infarction(NSTEMI), ST elevation myocardial infarction (STEMI), 
arrhythmia or heart failure)  estimated CTO duration, left main stem disease,  Syntax Score, 
number of significantly diseased vessels, J-CTO score, proximal LAD CTO, branch vessel 
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CTO (defined as diagonal, obtuse marginal, posterior descending artery, posterior left 
ventricular branch or distal circumflex artery in a right dominant circulation), Left ventricular 
systolic function, confirmed demonstrable ischaemia (confirmed evidence of ischaemia by 
non-invasive testing, the absence of which does not mean the absence of ischaemia), 
confirmed myocardial viability in the CTO territory (the absence of a resting left ventricular 
regional wall motion abnormality or confirmation by non-invasive testing in the presence of a 
wall motion abnormality, the absence of which does not mean the absence of viability), 
number of anti-anginal medications, warfarin use and loop diuretic use. The C-statistic for the 
propensity score model was 0.750 and the Hosmer-Lemeshow test for goodness of fit was 
0.778. To identify matched pairs of patients undergoing CTO PCI and elective medical 
therapy a 1:1 optimal match with a ±0.03 caliper and no replacement was used.  Cumulative 
survival was calculated using the Kaplan–Meier method.Clinical outcomes in the matched 
population were analysed with Cox proportional hazards regression stratified by matched-
pair.  
Two sub-group analyses amongst propensity matched patients were performed. We 
compared outcomes including only propensity matched-pairs in which the CTO PCI patient 
underwent successful PCI. The second sub-group analysis compared propensity matched 
patients only if the CTO territory of the CTO PCI patient had been revascularized by any 
means during the study period and the CTO territory of the medical therapy patient had not 
been revascularized. 
Stata v.12(StataCorp, College Station, Texas) was used for statistical analysis. 
Probability values were 2-sided, and values of p<.05 were considered significant. 
Results 
Of the 1957 patients identified in the cohort, a CTO was treated by PCI in 405(20.7%) 
and medical therapy in 667(34.1%), 885(45.2%) patients underwent CABG. In 23 patients, 
the only CTO identified was a non-dominant right coronary artery; these patients were 
excluded from analysis, leaving 1934 patients. Of those treated by PCI or medical therapy, 
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propensity score matching identified 294 pairs of patients. Table 1 lists demographic, clinical 
and angiographic characteristics by treatment group for the entire cohort and for propensity 
matched groups.  After propensity matching, no significant imbalance was identified in 
covariates between groups. 
Significant multi-variable predictors of 5-year mortality were age, elective medical 
therapy of the CTO, CKD>3, peripheral vascular disease, chronic lung disease, NYHA class, 
and ejection fraction<30% (table 2). 
Procedural details 
PCI of the CTO was successful in 250(61.7%) of all patients in whom the CTO was 
attempted and 177(60.2%) of the propensity matched group. In the propensity matched CTO 
PCI group, 88(29.9%) patients underwent PCI to another vessel other than the CTO vessel as 
part of their initial revascularization strategy, compared with 62(21.1%) in the group in which 
the CTO was treated medically. PCI was complicated by wire perforation in 4(1%) of CTO 
PCI procedures, all of which were included in the propensity matched group (1.4%). 
Pericardial drainage for tamponade was required in one patient, peri-procedural death 
occurred in one patient and two patients were managed conservatively. No wire perforations 
occurred in any patients in the cohort undergoing PCI to non-occlusive disease. In those in 
the propensity matched CTO PCI group treated by successful PCI, median total length of 
stented segments was 46mm(31-63mm). In those in the propensity matched medical therapy 
group in whom PCI to concomitant non-occlusive disease was performed, median total length 
of stented segment was 24mm(16-35mm). Drug eluting stents were used in 140(79.0%) of 
patients undergoing successful CTO PCI and 36(58.1%) of patients in the elective medical 
therapy group who underwent PCI to non-occlusive disease. 
5-year outcomes 
5-year outcomes for the entire cohort and propensity matched groups are listed in 
table 3. Mortality at 5 years in the propensity matched CTO PCI group was 11.6%, compared 
with 16.7% in the medical therapy group but did not quite reach conventional statistical 
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significance, hazard-ratio 0.63(0.40-1.00, p=.052)(figure 1). However the composite of death 
or myocardial infarction at 5 years occurred in 13.9% of the CTO PCI group and 19.6% in 
the elective medical therapy group, hazard-ratio 0.64(0.42 to 0.99), p=.043(figure 2). Repeat 
revascularization, unplanned in the initial treatment strategy was more common in the CTO 
PCI group than the elective medical therapy group. The majority of CTO PCI patients (51, 
73.9%) who underwent repeat, unplanned revascularization did not undergo successful initial 
CTO PCI. In the propensity matched CTO PCI group, 54(18.4%) patients underwent CABG 
within 5 years and 15(5.1%) underwent further PCI unplanned in the initial revascularization 
strategy. In the medical therapy group, 13(4.4%) underwent CABG within 5 years and 
22(7.5%) underwent subsequent PCI.  
Sub-group analyses 
If only the 177 matched pairs in which CTO PCI was successful were analyzed, there 
was no statistically significant difference in 5-year mortality or the 5-year composite of death 
or MI(supplementary figure 1 and table 4). However, the excess of repeat revascularization in 
the CTO PCI group was no longer evident (Supplementary figure 1).  
Of the 117 patients who underwent unsuccessful CTO PCI, 45(38%) underwent 
revascularization to the CTO territory during the 5 year follow-up period of which 44(98%) 
were by CABG. Median time to unplanned revascularization in this group was 243 days(183-
359).  Similarly, 20 of 294 patients treated by medical therapy underwent revascularization to 
the CTO territory during the 5 year follow-up period, 13(65%) by CABG and 7(35%) by PCI.  
There were 208 propensity matched-pairs in whom the CTO territory of the CTO PCI 
patient had been revascularized by any means during the study period and the CTO territory 
of the medical therapy patient had not been revascularized. There was a significant difference 
in mortality at 5 years, the composite of death or MI at 5 years and 5 year cardiac death, 
favouring the revascularized group(Supplementary figure 2 and table 4).  
Drug-eluting stents and target vessel revascularization after successful CTO PCI 
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 Of the 177 patients in the propensity matched group in whom PCI was successful, 18 
(10.2%) underwent repeat, unplanned revascularization in the 5-year study period(13 by PCI 
and 5 by CABG), of which 13(7.4%) patients underwent target vessel revascularization (12 
for in-stent restenosis and 1 for very late stent thrombosis). Of the 37(20.9%) patients in 
whom bare metal stents were used, repeat unplanned revascularization occurred in 5(13.5%) 
patients during the 5-year study period (4 by PCI and 1 by CABG), 3 of which were due to 
in-stent restenosis in the CTO vessel and 2 due to de novo disease in another vessel. Amongst 
the same successful CTO PCI group, 23(12.9%) patients died during the 5-year study period 
5(2.8%) of whom had undergone PCI with a bare metal stent. Similarly, 28(15.8%) of these 
patients suffered the composite of death or myocardial infarction during the study period, 
5(2.8%) of whom had undergone PCI with a bare metal stent. 
Discussion 
We present, in a propensity matched population well balanced for both clinical and 
angiographic characteristics, 5-year clinical outcomes comparing CTO PCI and elective 
medical therapy analyzed by intention-to-treat. We are unable to reject our null hypothesis 
(albeit by a narrow margin) that there is no difference in our primary outcome of 5-year all-
cause mortality between propensity matched CTO PCI and elective medical therapy groups. 
However, we do demonstrate a significant difference in the composite of 5-year death or MI 
favouring CTO PCI over elective medical therapy. The difference in outcomes appears to be 
driven by whether the CTO was revascularized, rather than whether it was treated by 
successful PCI. 
Procedural success 
The evidence describing long-term outcomes associated with CTO PCI is at present 
entirely observational and largely involves comparison of successful versus failed 
procedures3,4. A problem peculiar to PCI of CTOs compared to PCI of other coronary lesions 
is that procedural success rates are much lower. Although success rates as high as 85% have 
been reported14, the success rate in the UK between 2005 and 2009 was 70%4  and a recent 
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publication using data from The National Cardiovascular Data Registry CathPCI Registry, 
which included 22,365 attempts at CTO PCI in the USA between 2009 and 2013 reported a 
success rate of 59%15 . This has two important implications; firstly, in applying the evidence 
base we cannot necessarily put our patients in the more favourable successful group. 
Secondly, in investigating outcomes by the principle of intention-to-treat, a sizeable 
proportion of patients will not receive the intended treatment because of procedural failure. 
This may dilute the power of the study, or complicate comparison by including other 
treatment modalities, in this case CABG. Randomised trials investigating outcomes of CTO 
PCI are likely to be beset by the same problem.  
A survival benefit? 
It may be that our failure to demonstrate a difference in all-cause mortality between 
those treated by CTO PCI and medical therapy(figure 1) is due to insufficient sample size. 
This is supported by the numerical difference in mortality and by the presence of a 
statistically significant survival benefit when the composite of death or MI is used(figure 2). 
In spite of CTO PCI success rates of 60%, 76% of propensity matched CTO PCI patients 
underwent revascularization to the CTO territory compared with only 7% in the propensity 
matched medical therapy group. It would appear that the increased rate of repeat 
revascularization we report in the CTO PCI group(figure 2), absent if only successful cases 
are analyzed(supplementary figure 1) was related to an intention to revascularize and 
subsequent referral for CABG on failure of PCI. 
If it is revascularization of the CTO territory that is important, it is somewhat 
surprising that when only propensity matched pairs in which CTO PCI had been successful 
are analyzed there is a smaller numerical difference in mortality and death/MI(Supplementary 
figure 1). This could be a true finding, or might be explained by the loss of power as a result 
of including only 60% of propensity matched patients, and was perhaps contributed to by the 
comparison with some medical therapy patients who did in fact undergo revascularization of 
their CTO. In addition, it may be that CABG is associated with a greater survival benefit and 
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the exclusion of the failed CTO PCI patients who were revascularized by CABG has removed 
this effect. Although the numbers are small, there was a difference in cardiac death favouring 
the successful PCI group over medical therapy(table 4). The clear association with improved 
survival if only propensity matched pairs in which the CTO was revascularized in the CTO 
PCI patient and not revascularized in the medical therapy patient suggests it is 
revascularization of the CTO territory that is important in driving the association with 
improved outcomes (Supplementary figure 2). This is further supported by our multi-variable 
analysis of the entire cohort, which shows that elective medical therapy (or the lack of 
revascularization by CABG or PCI) to be independently predictive of 5-year mortality (table 
3). This is consistent with the findings of a recently published retrospective cohort study 
using a similar population16.   
Why should CTOs be any different? 
Why would prognostic gain be associated with PCI over medical therapy in the 
setting of a CTO but not in non-occlusive disease6–10? The presence of a CTO in a non-infarct 
related artery in patients who present with ST-elevation myocardial infarction is associated 
with inferior outcomes17,18. This may be related to a greater myocardial mass at jeopardy in 
the infarct related artery due to an additional contribution to collateral dependent 
myocardium. Another possible explanation is that of a reduction in ischaemic myocardium. 
Unlike some non-occlusive coronary stenoses included in clinical trials, provided the 
myocardium is viable, CTOs almost invariably result in inducible ischaemia19. A larger 
ischaemic burden is associated with an adverse prognosis20 and reducing that burden has been 
associated with improved clinical outcomes21. If the effect of PCI on outcome is assessed in 
patients only if they have demonstrable ischaemia, a clinical benefit associated with PCI 
seems more likely5. 
Despite the observational evidence, doubt remains as to whether CTO PCI itself 
confers a prognostic benefit over medical therapy. Ultimately this can only be answered by a 
randomised trial, two of which are ongoing (ClinicalTrials.gov numbers NCT01760083 and 
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NCT01078051). Given the low event rates reported here, it seems unlikely that any 
difference in the harder clinical outcomes of death or MI would become apparent until 
relatively late in the follow-up period.    
Limitations 
This study is limited by its observational nature; however the study population was 
very well balanced for both clinical and angiographic characteristics. Without randomization 
though, we cannot adjust for any unmeasured differences between groups. It is also limited 
by including only patients from a single centre. Because data was collected retrospectively, 
complete records of symptomatic status at follow-up were not collected and therefore control 
of symptoms and morbidity related to treatment could not be compared across groups.  The 
study benefited from comprehensive national audit data collection resulting in no known 
censored events and collection of robust hard endpoint data. Migration outside of England or 
Wales could result in missed events however there is no reason to suppose that this would 
introduce bias between groups.  
Finally, CTO PCI technique has progressed since the period of data collection and the 
success rates we report are lower than have been reported more recently4,14. As a 
consequence, a proportion of patients in the CTO PCI group were ultimately treated 
medically or by CABG. However, in an era of rapid development, to achieve 5-year clinical 
follow up, it is not possible for procedures to be entirely contemporary. Perhaps more 
importantly, a recent publication reporting over 22,000 attempts at CTO PCI in the USA 
between 2009-2013 reported success rates of only 59%15, lower than we report here. 
Although a proportion of patients underwent PCI with bare-metal stents, rates of repeat 
revascularization, and more importantly death or myocardial infarction were not sufficiently 
large in this group to influence our results. It seems unlikely that the use of third generation 
(rather than first and second generation) drug eluting stents would have greatly altered our 
results either. 
Conclusions 
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Using an alternative approach to much of the existing literature on the subject3,4, our 
findings support the suggestion that the revascularization of a CTO is associated with 
improved long-term survival. However from this study, we cannot attribute this finding to 
successful CTO PCI at the index procedure alone.       
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Figure legends 
 
Figure 1. Kaplan-Meier curves showing 5-year survival for propensity matched CTO PCI and 
medical therapy groups. 
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Figure 2. Kaplan-Meier curves showing 5-year composite of death or myocardial 
infarction(top) and 5-year unplanned repeat revascularization for propensity matched CTO 
PCI and medical therapy groups. 
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Supplementary figure 1. Kaplan-Meier curves showing 5-year survival(top), composite of death or 
MI(middle) and repeat revascularization for propensity matched CTO PCI and medical therapy 
groups including only matched pairs in which CTO PCI was successful. 
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Supplementary figure 2. Kaplan-Meier curves showing 5-year survival(top) and composite of death or 
MI(bottom) for propensity matched CTO PCI and corresponding elective medical therapy groups 
including only matched pairs in which during the follow-up period, the CTO was revascularized in the 
CTO PCI patient and the CTO was not revascularized in the medical therapy patient. 
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Text Tables 
Table 1. Baseline characteristics in entire cohort and propensity matched groups. 
 Entire cohort  (n=1934) Propensity matched groups (n=588) 
 CABG 
 
n=878 
CTO PCI 
 
n=405 
Medical 
therapy 
n=651 
p-value* Standardised 
difference* 
CTO PCI 
 
n=294 
Medical 
therapy 
n=294 
p-
value* 
Standardised 
difference* 
Age 66.0+9.3 63.2+10.1 65.8+10.7 p<.001 -0.257 64.3±10.0 63.9±10.2 p=.645 0.038 
Male gender 728(82.9) 301(73.1) 506(77.7) p=.205 -0.080 220(74.8) 220(74.8) p=1.00 0.000 
Previous MI 454(51.7) 202(49.9) 394(60.5) p=.001 -0.215 151(51.4) 143(48.6) p=.563 -0.048 
Previous PCI 41(4.7) 22(5.4) 64(9.8) p=.011 -0.166 18(6.1) 24(8.2) p=.337 -0.079 
Diabetes  193(22.0) 78(19.3) 137(21.0) p=.484 -0.044 62(21.1) 53(18.0) p=.349 0.077 
Smoking  
Ex 
Current 
 
471(53.6) 
148(16.9) 
 
200(49.4) 
73(18.0) 
 
306(47.0) 
160(24.5) 
p=.037 
 
 
0.048 
-0.160 
 
142(48.3) 
56(19.1) 
 
141(48.0) 
62(21.1) 
p=.802 
 
 
 
0.007 
-0.051 
PVD 115(13.1) 38 (9.4) 103(15.8) p=.003 -0.195 28(9.5) 31(10.5) p=.681 -0.034 
Hypertension 554(63.1) 225(55.6) 349(53.6) p=.537 0.039 159(54.1) 157(53.4) p=.869 0.014 
Hypercholestero-
laemia 
563(64.2) 199(49.1) 293(45.0) p=.191 0.083 146(49.7) 135(45.9) p=.364 0.075 
Family History 268(30.5) 152(37.5) 198(30.4) p=.017 0.151 107(36.4) 103(35.0) p=.731 0.028 
CKD >3 235(26.8) 82(20.3) 179(27.5) p=.005 -0.181 59(20.1) 64(21.8) p=.879 -0.042 
Chronic lung 
disease 
52(5.9) 23(5.7) 51(7.8) p=.182 -0.086 19(6.5) 15(5.1) p=.480 0.058 
Cerebrovascular 
disease 
65(7.4) 22(5.4) 61(9.4) p=.021 -0.151 17(5.8) 20(6.8) p=.610 -0.042 
CCS class 
No Angina 
I 
II 
III 
IV 
 
24(2.7) 
326(37.1) 
269(30.6) 
216(24.6) 
43(4.9) 
 
1(0.3) 
192(47.4) 
138(34.1) 
72(17.8) 
2(0.5) 
 
63(9.7) 
309(47.5) 
181(27.8) 
92(14.1) 
6(0.9) 
p<.001 
 
 
-0.445 
-0.001 
0.136 
0.100 
-0.051 
 
1(0.3) 
153(52.0) 
100(34.0) 
38(12.9) 
2(0.7) 
 
0(0) 
156(53.1) 
92(31.3) 
45(15.3) 
1(0.3) 
p=.683  
0.082 
-0.020 
0.058 
-0.068 
-0.008 
NYHA Class 
I 
II 
III 
IV 
 
503(57.3) 
267(30.4) 
97(11.0) 
11(1.3) 
 
298(73.6) 
95(23.5) 
12(3.0) 
0(0) 
 
414(63.6) 
155(23.8) 
74(11.4) 
8(1.2) 
p=.001 
 
 
0.216 
-0.008 
-0.330 
-0.158 
 
217(73.8) 
67(22.8) 
10(3.4) 
0(0) 
 
217(73.8) 
68(23.1) 
9(3.1) 
0(0) 
p=.970  
 
-0.008 
0.019 
- 
Presentation 
Stable angina 
UA/NSTEMI 
STEMI 
Arrhythmia 
Heart Failure 
 
645(73.5) 
194(22.1) 
15(1.7) 
11(1.3) 
13(1.5) 
 
371(91.6) 
32(7.9) 
1(0.3) 
1(0.3) 
0(0) 
 
491(75.4) 
86(13.2) 
11(1.7) 
33(5.1) 
30(4.6) 
p<.001 
 
 
0.446 
-0.173 
-0.148 
-0.303 
-0.311 
 
265(90.1) 
27(9.2) 
1(0.3) 
1(0.3) 
0(0) 
 
268(91.2) 
26(8.8) 
0(0) 
0(0) 
0(0) 
p=.565  
0.012 
0.082 
0.082 
0.082 
- 
Occlusion 
duration 
(months) 
16(8-52) 12(6-24) 16(8-56) p<.001 -0.372 12(7-26) 12(7-29) p=.551 0.039 
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LMS disease 184(21.0) 1(0.3) 23(3.5) p<.001 -0.243 1(0.3) 1(0.3)  0 
Syntax score 24(19-29) 14.5(10-19) 14.5(9-21.5) p=.359 -.197 14.5(10-19) 13.3(9-18.5) p=.106 0.034 
Diseased vessels 
1 
2 
3 
 
74(8.4) 
276(31.4) 
528(60.1) 
 
193(47.7) 
159(39.3) 
53(13.1) 
 
293(45.0) 
223(34.3) 
135(20.7) 
p<.001 
 
 
0.053 
0.104 
-0.205 
 
146(46.3) 
114(38.8) 
44(15.0) 
 
144(9.0) 
106(36.1) 
44(15.0) 
p=.771  
 
0.056 
0.000 
J-CTO score 
0 
1 
2 
>3 
 
210(23.9) 
355(40.4) 
243(27.7) 
70(8.0) 
 
162(40.0) 
153(37.8) 
76(18.8) 
14(3.5) 
 
182(28.0) 
250(38.4) 
168(25.8) 
51(7.8) 
p<.001 
 
 
0.256 
-0.013 
-0.170 
-0.190 
 
109(37.1) 
113(38.4) 
60(20.4) 
12(4.0) 
 
109(37.1) 
114(38.8) 
59(20.1) 
12(4.0) 
p=1.00  
0.000 
-0.007 
0.008 
0.000 
Proximal LAD 
CTO 
138(15.7) 53(13.1) 90(13.8) p=.733 -0.022 37(12.6) 32(10.9) p=.522 0.053 
Branch vessel 
CTO 
114(13.0) 42(10.4) 115(17.7) p=.001 -0.211 38(12.9) 43(14.6) p=.550 -0.049 
LV function 
Good(EF >50%) 
Mod(EF 30-
50%) 
Poor(EF <30%) 
 
527(60.0) 
246(28.0) 
105(12.0) 
 
304(75.1) 
88(21.7) 
13(3.2) 
 
363(55.8) 
163(25.0) 
125(19.2) 
p<.001 
 
 
0.414 
-0.078 
-0.524 
 
213(72.5) 
68(23.1) 
 
13(4.4) 
 
220(74.8) 
60(20.4) 
 
14(4.8) 
p=.722  
-0.054 
0.066 
 
-0.016 
Confirmed 
ischaemia† 
491(55.9) 279(68.9) 356(54.7) p<.001 0.295 204(69.4) 198(67.4) p=.595 0.044 
Confirmed 
viability† 
551(62.8) 322(79.5) 369(56.7) p<.001 0.505 222(75.5) 220(74.8) p=.849 0.016 
N anti-anginals 
0 
1 
2 
3 
4 
 
159(18.1) 
332(37.8) 
260(29.6) 
106(12.1) 
21(2.4) 
 
85(21.0) 
150(37.0) 
126(31.1) 
38(9.4) 
6(1.5) 
 
182(28.0) 
262(40.3) 
130(20.0) 
67(10.3) 
10(1.5) 
p=.001  
-0.162 
-0.066 
0.257 
-0.031 
-0.004 
 
73(24.8) 
114(38.8) 
76(25.9) 
28(9.5) 
3(1.0) 
 
72(24.5) 
113(38.4) 
77(26.2) 
30(10.2) 
2(0.7) 
p=.991  
 
0.007 
-0.008 
-0.023 
0.037 
Loop diuretic 121(13.8) 30(7.4) 139(21.4) p<.001 -0.405 26(8.8) 22(7.5) p=.547 0.050 
Warfarin 29(3.3) 13(3.2) 41(6.3) p=.027 -0.145 3(1.0) 10(3.4) p=.050 -0.162 
*p-values and standardised differences compare CTO PCI and medical therapy groups only. †Confirmed viability/ischaemia only. 
 Table 2. Multi-variable predictors of 5 year mortality for the entire cohort (n=1934) 
 Multi-variable analysis 
 HR 95% CI p-value 
Medical therapy* 
 
1.56 1.25-1.94 p<.001 
Age(years) 
 
1.05 1.04-1.07 p<.001 
Diabetes 
 
1.30 1.04-1.67 p=.023 
CKD >3 
 
1.42 1.17-1.72 p<.001 
PVD 
 
1.63 1.27-2.09 p<.001 
Chronic lung disease 
 
1.72 1.26-2.37 p=.001 
Presentation with heart failure 
 
1.70 1.09-2.66 p=.019 
NYHA class 
II 
III 
IV 
 
 
1.60 
1.87 
6.01 
 
1.24-2.06 
1.34-2.59 
3.30-10.95 
 
p<.001 
p<.001 
p<.001 
Poor LV function (EF <30%) 2.05 1.56-2.68 p<.001 
   *Elective medical therapy of the CTO 
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Table 3. Outcome comparisons for the entire cohort(left) and propensity matched groups(right). 
 Entire Cohort Propensity matched groups 
 Number of events (%)   Number of events (%)   
Outcome CTO 
PCI 
n=405 
Medical 
Therapy 
n=667 
 
Hazard-Ratio p-
value 
CTO PCI 
 
n=294 
Medical 
Therapy 
n=294 
Hazard-Ratio  
(95% CI) 
p-
value 
5-year mortality 
 
 
43(10.6) 170(26.1) 0.37(0.26-
0.51) 
p<.001 34(11.6) 49(16.7) 0.63(0.40-1.00) p=.052 
5-year cardiac 
death 
 
 
23(5.7) 71(10.9) 0.47(0.30-
0.76) 
p=.002 14(4.8) 19(6.5) 0.65(0.30-1.38) p=.261 
5-year death/MI 
 
 
56(13.8) 187(28.7) 0.44(0.32-
0.59) 
p<.001 41(13.9) 57(19.6) 0.64(0.42-0.99) p=.043 
5-year unplanned 
revascularization 
 
96(23.7) 76(11.7) 2.06(1.52-
2.78) 
p<.001 69((23.5) 35(11.9) 1.81(1.18-2.79) p=.007 
 
Table 4.  Outcome comparisons including only propensity matched pairs in which CTO PCI was successful(left) and 
including only matched pairs in which during the follow-up period, the CTO was revascularized in the CTO PCI 
patient and the CTO was not revascularized in the medical therapy patient(right). 
 Succesful CTO PCI only Revascularized CTO vs not revascularized 
 Number of events (%)   Number of events (%)   
Outcome CTO 
PCI 
n=177 
Medical 
Therapy 
n=177 
 
Hazard-Ratio p-
value 
CTO PCI 
 
n=208 
Medical 
Therapy 
n=208 
Hazard-Ratio  
(95% CI) 
p-value 
5-year mortality 
 
 
23(13) 29(16.4) 0.74(0.42-
1.32) 
p=.309 22(10.6) 38(18.3) 0.50(0.28-0.88) p=.016 
5-year cardiac 
death 
 
 
5(2.8) 12(6.8) 0.27(0.08-
0.98) 
p=.046 6(2.8) 15(7.2) 0.21(0.06-0.75) p=.015 
5-year death/MI 
 
 
28(15.8) 32(18.1) 0.79(0.46-
1.37) 
p=.406 27(13.0) 43(20.7) 0.53(0.31-0.89) p=.017 
5-year unplanned 
revascularization 
18(10.2) 21(11.9) 0.70(0.35-
1.39) 
p=.306     
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